Actelion files new PAH treatment Uptravi
This article was originally published in Scrip
Actelion has made its first regulatory filing for its novel treatment for pulmonary arterial hypertension (PAH), selexipag, in the EU as Uptravi. Further submissions, including to the US FDA, are "forthcoming", it said.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.